Patents by Inventor Phillip Dan Cook

Phillip Dan Cook has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 6399754
    Abstract: Compositions and methods are provided for the treatment and diagnosis of diseases amenable to modulation of the production of selected proteins. In accordance with preferred embodiments, oligonucleotides and oligonucleotide analogs are provided which are specifically hybridizable with a selected sequence of RNA or DNA wherein at least one of the 2′-deoxyfuranosyl moieties of the nucleoside unit is modified. Treatment of diseases caused by various viruses and other causative agents is provided.
    Type: Grant
    Filed: August 17, 1998
    Date of Patent: June 4, 2002
    Assignee: ISIS Pharmaceuticals, Inc.
    Inventor: Phillip Dan Cook
  • Patent number: 6395492
    Abstract: Linked nucleosides having at least one functionalized nucleoside that bears a substituent such as a steroid molecule, a reporter molecule, a non-aromatic lipophilic molecule, a reporter enzyme, a peptide, a protein, a water soluble vitamin, a lipid soluble vitamin, an RNA cleaving complex, a metal chelator, a porphyrin, an alkylator, a pyrene, a hybrid photonuclease/intercalator, or an aryl azide photo-crosslinking agent exhibit increased cellular uptake and other properties. The substituent can be attached at the 2′-position of the functionalized nucleoside via a linking group.
    Type: Grant
    Filed: August 7, 2000
    Date of Patent: May 28, 2002
    Assignee: ISIS Pharmaceuticals, Inc.
    Inventors: Muthiah Manoharan, Phillip Dan Cook, Clarence Frank Bennett
  • Publication number: 20020049163
    Abstract: Oligonucleotide-folate conjugates are described wherein folates are conjugated to one or more sites on an oligonucleotide including the 2′-, 3′-, 5′-, nucleobase and internucleotide linkage sites. The folate can be attached via the &agr;- or &ggr;-carboxylate, optionally through a linking group. Methods for the regiospecific synthesis of the conjugates are diclosed. Also disclosed are nucleosidic and non-nucleosidic linkers conjugated to folic acid and related folates.
    Type: Application
    Filed: October 9, 2001
    Publication date: April 25, 2002
    Applicant: ISIS Pharmaceuticals, Inc.
    Inventors: Phillip Dan Cook, Muthiah Manoharan, Balkrishen Bhat, Andrel P. Guzzev
  • Patent number: 6369040
    Abstract: Novel 2- and 4-substituted pyrimidine nucleosides and oligonucleosides are provided, as are methods and intermediates useful in preparing same.
    Type: Grant
    Filed: August 27, 1999
    Date of Patent: April 9, 2002
    Assignee: Isis Pharmaceuticals, Inc.
    Inventors: Oscar L. Acevedo, Martin G. Dunkel, Phillip Dan Cook
  • Patent number: 6358931
    Abstract: Compositions and methods for modulating the activity of RNA are disclosed, In accordance with preferred embodiments, antisense compositions are prepared targeting reactive portions. The reactive portions preferably comprise one or two imidazole functionalities conjugated to the targeting oligonucleotide via linkers with or without intervening intercalating moieties. Therapeutics, diagnostics and research methods also are disclosed, as are synthetic nucleosides and nucleoside fragments that can be elaborated into oligonucleotides.
    Type: Grant
    Filed: August 30, 1994
    Date of Patent: March 19, 2002
    Assignee: ISIS Pharmaceuticals, Inc.
    Inventors: Phillip Dan Cook, Thomas Bruice, Charles John Guinosso, Andrew Mamoru Kawasaki, Richard Griffey
  • Patent number: 6359124
    Abstract: Compositions and methods are provided for the modulation of expression of the human ras gene in both the normal and activated forms. Oligonucleotides are provided that have methylene(methylimino) linkages alternating with phosphorothioate or phosphodiester linkages. Further oligonucleotides are provide that have a first region having a methylene(methylimino) linkage alternating with a phosphorothioate or phosphodiester linkage and a second region having phosphorothioate linkages. Such oligonucleotides can be used for diagnostics as well as for research purposes including methods for diagnosis, detection and treatment of conditions arising from the activation of the H-ras gene.
    Type: Grant
    Filed: February 12, 1999
    Date of Patent: March 19, 2002
    Assignee: ISIS Pharmaceuticals, Inc.
    Inventors: David J. Ecker, Phillip Dan Cook, Brett P. Monia, Susan M. Freier, Yogesh S. Sanghvi
  • Publication number: 20020009748
    Abstract: Mixtures of chemical compounds are provided having antibacterial and other utility. The mixtures are formed, preferably in solution phase, from the reaction of a purine or pyrimiding heterocyclic scaffold with a set of related chemical substituients, optionally through employment of a tether moiety. Libraries formed in accordance with the invention have utility per se and are articles of commerce. They can be used to screen for pesticides, drugs and other biologically active compounds.
    Type: Application
    Filed: May 13, 1998
    Publication date: January 24, 2002
    Inventor: PHILLIP DAN COOK
  • Patent number: 6339066
    Abstract: Compositions and methods are provided for the treatment and diagnosis of diseases associated with the expression of one or more of the &bgr;I, &bgr;II, &ggr;, &dgr;, &egr;, &zgr; or &eegr; isoforms (isozymes) of protein kinase C (PKC). Oligonucleotides are provided which are targeted to nucleic acids encoding PKC-&bgr;I, PKC-&bgr;II, PKC-&ggr;, PKC-&dgr;, PKC-&egr;, PKC-&zgr; or PKC-&eegr;. Provided herein are oligonucleotides specifically hybridizable with a translation initiation site, 5′-untranslated region, 3′-untranslated region or other targeted region of a &bgr;I, &bgr;II, &ggr;, &dgr;, &egr;, &zgr; or &eegr; isoform of PKC, wherein at least about 75% of the nucleoside units of a given oligonucleotide are joined together by a stereospecific (i.e., Sp or Rp) phosphorothioate 3′ to 5′ linkages. In preferred embodiments, the oligonucleotides of the disclosure additionally contain one or more chemical modifications.
    Type: Grant
    Filed: March 31, 1997
    Date of Patent: January 15, 2002
    Assignee: ISIS Pharmaceuticals, Inc.
    Inventors: C. Frank Bennett, Nicholas M. Dean, Phillip Dan Cook, Glenn Hoke
  • Patent number: 6335434
    Abstract: Oligonucleotide-folate conjugates are described wherein folates are conjugated to one or more sites on an oligonucleotide including the 2′-, 3′-, 5′-, nucleobase and internucleotide linkage sites. The folate can be attached via the &agr;- or &ggr;-carboxylate, optionally through a linking group. Methods for the regiospecific synthesis of the conjugates are diclosed. Also disclosed are nucleosidic and non-nucleosidic linkers conjugated to folic acid and related folates.
    Type: Grant
    Filed: March 24, 1999
    Date of Patent: January 1, 2002
    Assignee: ISIS Pharmaceuticals, Inc.,
    Inventors: Andrei P. Guzaev, Phillip Dan Cook, Muthiah Manoharan, Balkrishen Bhat
  • Patent number: 6329523
    Abstract: Novel compounds having the formula: wherein the constituent variables are defined herein. The compounds are constructed to include a central aromatic, aliphatic, or heterocyclic ring system. Attached to the central ring system are two linear groups having nitrogenous moieties that are derivatized with chemical functional groups. The ring system can include further nitrogenous moieties, either as ring atoms or on pendant groups attached to the ring, that may also be derivatized with chemical functional groups. The totality of the chemical functional groups imparts certain conformational and other properties to the these compounds. In accordance with certain embodiments of the invention, libraries of such compounds are prepared utilizing permutations and combinations of the chemical functional groups and the nitrogenous moieties to build complexity into the libraries.
    Type: Grant
    Filed: March 10, 1999
    Date of Patent: December 11, 2001
    Assignee: ISIS Pharmaceuticals, Inc.
    Inventors: Phillip Dan Cook, Haoyun An
  • Patent number: 6326199
    Abstract: Oligonucleotides and other macromolecules are provided that have increased nuclease resistance, substituent groups for increasing binding affinity to complementary strand, and sub-sequences of 2′-deoxy-erythro-pentofuranosyl nucleotides that activate RNase H enzyme. Such oligonucleotides and macromolecules are useful for diagnostics and other research purposes, for modulating protein in organisms, and for the diagnosis, detection and treatment of other conditions susceptible to antisense therapeutics.
    Type: Grant
    Filed: December 1, 1999
    Date of Patent: December 4, 2001
    Assignee: ISIS Pharmaceuticals, Inc.
    Inventors: Phillip Dan Cook, Brett P. Monia
  • Patent number: 6322987
    Abstract: Nucleosides and oligonucleosides functionalized to include carbamate functionality, and derivatives thereof. In certain embodiments, the compounds of the invention further include steroids, reporter molecules, reporter enzymes, lipophilic molecules, peptides or proteins attached to the nucleosides through the carbamate group.
    Type: Grant
    Filed: October 16, 2000
    Date of Patent: November 27, 2001
    Assignee: ISIS Pharmaceuticals, Inc.
    Inventors: Phillip Dan Cook, Muthiah Manoharan
  • Publication number: 20010044145
    Abstract: The present invention relates to methods for using mammalian RNase H and compositions thereof, particularly for reduction of a selected cellular RNA target via antisense technology.
    Type: Application
    Filed: March 5, 2001
    Publication date: November 22, 2001
    Inventors: Brett P. Monia, Phillip Dan Cook, Stanley T. Crooke, Walter Lima, Hongjiang Wu
  • Patent number: 6320040
    Abstract: Tetrahydrofuranyl compounds are provided that are functionalized to include pendant conjugate groups, and which are useful in diagnosis assays and as research reagents. Novel intermediates for the synthesis of the compounds are also provided.
    Type: Grant
    Filed: October 7, 1999
    Date of Patent: November 20, 2001
    Assignee: ISIS Pharmaceuticals, Inc.
    Inventors: Phillip Dan Cook, Kelly Teng
  • Publication number: 20010027251
    Abstract: Novel compounds that mimic and/or modulate the activity of wild-type nucleic acids. In general, the compounds are phosphorothioate oligonucleotides wherein the 5′-terminal internucleoside linkage or the 5′- and 3′-terminal linkages are modified.
    Type: Application
    Filed: March 14, 2001
    Publication date: October 4, 2001
    Applicant: ISIS Pharmaceuticals, Inc.
    Inventors: Phillip Dan Cook, Muthiah Manoharan
  • Patent number: 6277603
    Abstract: Macromolecules are provided that have increased nuclease resistance, increasing binding affinity to a complementary strand, and that activate RNase H enzyme. The macromolecules have the structure PNA-DNA-PNA where the DNA portion is composed of subunits of 2′-deoxy-erythro-pento-furanosyl nucleotides and the PNA portions are composed of subunits of peptide nucleic acids. Such macromolecules are useful for diagnostics and other research purposes, for modulating protein in organisms, and for the diagnosis, detection and treatment of other conditions susceptible to therapeutics.
    Type: Grant
    Filed: July 1, 1998
    Date of Patent: August 21, 2001
    Assignee: ISIS Pharmaceuticals, Inc.
    Inventor: Phillip Dan Cook
  • Patent number: 6277982
    Abstract: Methods for the alkylation of alcohols, amines and thiols by the use of cyclic sulfates are disclosed. The alkylated sulfates formed are versatile intermediates which may be further elaborated by methods of the invention. In particular, methods for the alkylation of the 2′, 3′ or 5′-hydroxy position of nucleosides and nucleoside analogs with cyclic sulfates to form the 2′, 3′ or 5′-O-alkyl sulfate modified compounds are disclosed. Displacement of the 2′,3′ or 5′-O-sulfate with a nucleophile provides 2′, 3′ or 5′-O-modified nucleosides and nucleoside analogs useful for the synthesis of oligomeric compounds having improved hybridization affinity and nuclease resistance.
    Type: Grant
    Filed: August 20, 1999
    Date of Patent: August 21, 2001
    Assignee: ISIS Pharmaceuticals, Inc.
    Inventors: Allister S. Fraser, Muthiah Manoharan, Phillip Dan Cook, Michael E. Jung, Andrew M. Kawasaki
  • Patent number: 6265558
    Abstract: Nucleosides and linked nucleosides functionalized to include alkylthiol chemical functionality at ribofuranosyl positions, nucleosidic base positions, or on internucleoside linkages. In certain embodiments, the compounds of the invention further include steroids, reporter molecules, reporter enzymes, lipophilic molecules, peptides or proteins attached to the nucleosides through the alkylthio group.
    Type: Grant
    Filed: August 26, 1999
    Date of Patent: July 24, 2001
    Assignee: ISIS Pharmaceuticals, Inc.
    Inventors: Phillip Dan Cook, Muthiah Manoharan
  • Publication number: 20010008936
    Abstract: Sequence-specific oligonucleotides are provided having substantially pure chiral Sp phosphorothioate, chiral Rp phosphorothioate, chiral Sp alkylphosphonate, chiral Rp alkylphosphonate, chiral Sp phosphoamidate, chiral Rp phosphoamidate, chiral Sp phosphotriester, and chiral Rp phosphotriester linkages. The novel oligonucleotides are prepared via a stereospecific SN2 nucleophilic attack of a phosphodiester, phosphorothioate, phosphoramidate, phosphotriester or alkylphosphonate anion on the 3′ position of a xylonucleotide. The reaction proceeds via inversion at the 3′ position of the xylo reactant species, resulting in the incorporation of phosphodiester, phosphorothioate, phosphoramidate, phosphotriester or alkylphosphonate linked ribofuranosyl sugar moieties into the oligonucleotide.
    Type: Application
    Filed: February 16, 2001
    Publication date: July 19, 2001
    Inventor: Phillip Dan Cook
  • Patent number: 6262241
    Abstract: Compositions and methods for modulating the activity of RNA and DNA are disclosed. In accordance with preferred embodiments, antisense compositions are prepared comprising targeting and reactive portions. Reactive portions which act, alternatively, through phosphorodiester bond cleavage, through backbone sugar bond cleavage or through base modification are preferrably employed. Groups which improve the pharmacodynamic and pharmacokinetic properties of the oligonucleotides are also useful in accordance with certain embodiments of this invention. Delivery of the reactive or non-reactive functionalities into the minor groove formed by the hybridization of the composition with the target RNA is also preferrably accomplished. Therapeutics, diagnostics and research methods and also disclosed. Synthetic nucleosides and nucleoside fragments are also provided useful for elaboration of oligonucleotides and oligonucleotide analogs for such purposes.
    Type: Grant
    Filed: February 3, 1995
    Date of Patent: July 17, 2001
    Assignee: Isis Pharmaceuticals, Inc.
    Inventors: Phillip Dan Cook, David J. Ecker, Charles John Guinosso, Oscar Leobardo Acevedo, Andrew Kawasaki, Kandasamy Ramasamy